Brief: Cantargia's CAN10 For Treatment Of Systemic Sclerosis Gets Orphan Drug Designation From FDA

Cantargia AB

06/09/2023 07:09

Sept 6 (Reuters) - Cantargia AB  CANTA.ST :
    * FDA GRANTS ORPHAN DRUG DESIGNATION TO CAN10 FOR TREATMENT
OF
SYSTEMIC SCLEROSIS
    * INITIAL DATA FROM TRIAL ARE EXPECTED IN 2024

Source text for Eikon:  ID:nMFNb6RX0b 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))